Surgical Science (Q2 initial take): A reassuring quarter - Redeye

Surgical Science delivered a strong Q2, with sales 6% above our expectations and an EBIT margin of 13% versus our 9% estimate. We are also encouraged by the reassessment of the potential revenue impact from the non-materialised Intuitive MoU. We expect the share to react positively to the report today by 5–10%.

Länk till analysen i sin helhet: https://www.redeye.se/research/1179841/surgical-science-q2-initial-take-a-reassuring-quarter?utm_source=finwire&utm_medium=RSS